3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets
Cardiff Oncology Inc CRDF
$1.17
▼ -2.50%
($-0.03)
Open
$1.19
Prev Close
$1.20
Day Range
$1.16 – $1.24
52W Range
$0.76 – $3.31
Market Cap
$91.02M
Beta
1.50
EPS (TTM)
$-0.59
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2004-07-27 |
| Shares Out. | 77,800,000 |
| Website | cardiffoncology.com/ ↗ |
| Phone | 13026365400 |
| Employees | 31 |
| Revenue | $104,000 |
| Gross Profit | $104,000 |
| Net Income | -$9.2M |
| Free Cash Flow | -$40.9M |
| Total Assets | $37.3M |
| Total Liabilities | $10.8M |
| Equity | $26.5M |
About Cardiff Oncology Inc
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
Cardiff Oncology Inc is a publicly traded company under the ticker symbol CRDF on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-09-01)